Skip to search formSkip to main contentSkip to account menu

diflomotecan

Known as: (5R)-5-Ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-3H,15H-oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The current work integrates cell-cycle dynamics occurring in the bone marrow compartment as a key element in the structure of a… 
Review
2009
Review
2009
Diflomotecan, a 10,11-difluoro-homocamptothecin, represents a new promising class of topoisomerase I inhibitors with enhanced… 
Review
2008
2008
2008
Homocamptothecins (hCPTs) are a novel class of topoisomerase I (Top1) inhibitors with enhanced chemical stability compared with… 
2006
2006
Two practical, efficient, and scalable asymmetric routes to DE ring fragment 7, a key building block in the synthesis of the… 
2005
2005
Purpose: To determine the maximum tolerated dose (MTD) of intravenous (iv) diflomotecan administered once every 3 weeks, and to… 
Highly Cited
2004
Highly Cited
2004
Review
2003
Review
2003
  • C. Bailly
  • Critical reviews in oncology/hematology
  • 2003
  • Corpus ID: 36196901
2003
2003
PURPOSE Diflomotecan (BN80915) is an E-ring modified camptothecin analogue that possesses greater lactone stability in plasma… 
Review
2002
Review
2002
Camptothecin analogues and derivatives appear to exert their antitumour activity by binding to topoisomerase I and have shown…